Probiotic Bacteria for Targeted Drug Delivery: Potential Applications in Cancer Therapy

Nikita

doi:10.36676/jrps.v15.i3.1476

Authors

Nikita M.Sc. in Medical Biotechnology, MDU Rohtak

DOI:

https://doi.org/10.36676/jrps.v15.i3.1476

Keywords:

Probiotic Bacteria, Targeted Drug Delivery, Cancer Therapy, Drug Delivery Systems, Tumor Targeting, Genetic Engineering, Encapsulation Techniques

Abstract

Conventional cancer treatments like radiation and chemotherapy frequently fail to meet expectations owing to side effects include systemic toxicity, lack of selectivity, and drug resistance. Targeted medication delivery systems have recently gained attention as a potential way to improve treatment effectiveness while reducing side effects. This research delves at the idea of using probiotic bacteria as a fresh way to deliver drugs to specific areas in cancer treatment. Due to their unique properties, such as their ability to colonise specific environments, interact with the immune system, and be engineered for targeted actions, probiotic bacteria have the potential to enhance drug delivery systems. These bacteria are traditionally known for their beneficial effects on gut health. This paper provides a comprehensive overview of the latest developments in the use of probiotic bacteria to deliver anti-cancer medications to tumour areas. It delves into the various methods of action, such as encapsulation techniques, genetic alterations, and the capacity to target the tumour microenvironment. The article emphasises the benefits of utilising probiotic bacteria, including their compatibility with the body, capacity to control immunological responses, and less systemic toxicity in comparison to traditional medicine delivery methods. On top of that, the article delves into the present status of clinical and preclinical research, highlighting important studies that prove the effectiveness and safety of drug delivery systems based on probiotics in cancer treatment. “The field is viewed in its entirety, including challenges such as regulatory barriers, strain selection, and potential safety concerns. Possible applications of probiotic bacteria in cancer treatment are discussed, such as boosting the efficacy of immunotherapy and chemotherapy drugs. We recommend more studies to look into genetically engineered probiotics, how they interact with cancer cells, and how to evaluate their safety over the long run.

References

Cano-Garrido, O., Seras-Franzoso, J., & Garcia-Fruitós, E. (2015). Lactic acid bacteria: Reviewing the potential of a promising delivery live vector for biomedical purposes. Microbial Cell Factories, 14(1), 137. https://doi.org/10.1186/s12934-015-0313-6 DOI: https://doi.org/10.1186/s12934-015-0313-6

Chung, Y., Ryu, Y., An, B. C., Yoon, Y.-S., Choi, O., Kim, T. Y., Yoon, J., Ahn, J. Y., Park, H. J., Kwon, S.-K., Kim, J. F., & Chung, M. J. (2021). A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome, 9(1), 122. https://doi.org/10.1186/s40168-021-01071-4 DOI: https://doi.org/10.1186/s40168-021-01071-4

Deepali, S., Mahesh, G., & Ganesh, G. (2019). Probiotics, their Health Benefits and Applications for Development of Human Health: A Review. Journal of Drug Delivery.

Dicks, L. M. T., & Vermeulen, W. (2022). Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play? Microorganisms, 10(9), 1733. https://doi.org/10.3390/microorganisms10091733 DOI: https://doi.org/10.3390/microorganisms10091733

Mueller, A.-L., Brockmueller, A., Fahimi, N., Ghotbi, T., Hashemi, S., Sadri, S., Khorshidi, N., Kunnumakkara, A. B., & Shakibaei, M. (2022). Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment. Biomedicines, 10(4), 832. https://doi.org/10.3390/biomedicines10040832 DOI: https://doi.org/10.3390/biomedicines10040832

Sachin, K., & Karn, S. K. (2021). Microbial Fabricated Nanosystems: Applications in Drug Delivery and Targeting. Frontiers in Chemistry, 9, 617353. https://doi.org/10.3389/fchem.2021.617353 DOI: https://doi.org/10.3389/fchem.2021.617353

Sawant, S. S., Patil, S. M., Gupta, V., & Kunda, N. K. (2020). Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. International Journal of Molecular Sciences, 21(20), 7575. https://doi.org/10.3390/ijms21207575 DOI: https://doi.org/10.3390/ijms21207575

Sedighi, M., Zahedi Bialvaei, A., Hamblin, M. R., Ohadi, E., Asadi, A., Halajzadeh, M., Lohrasbi, V., Mohammadzadeh, N., Amiriani, T., Krutova, M., Amini, A., & Kouhsari, E. (2019). Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. Cancer Medicine, 8(6), 3167–3181. https://doi.org/10.1002/cam4.2148 DOI: https://doi.org/10.1002/cam4.2148

Song, W., Anselmo, A. C., & Huang, L. (2019). Nanotechnology intervention of the microbiome for cancer therapy. Nature Nanotechnology, 14(12), 1093–1103. https://doi.org/10.1038/s41565-019-0589-5 DOI: https://doi.org/10.1038/s41565-019-0589-5

Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022). Cancer pharmacomicrobiomics: Targeting microbiota to optimise cancer therapy outcomes. Gut, 71(7), 1412–1425. https://doi.org/10.1136/gutjnl-2021-326264 DOI: https://doi.org/10.1136/gutjnl-2021-326264

Wei, X., Du, M., Chen, Z., & Yuan, Z. (2022). Recent Advances in Bacteria-Based Cancer Treatment. Cancers, 14(19), 4945. https://doi.org/10.3390/cancers14194945 DOI: https://doi.org/10.3390/cancers14194945

Yuksel, N., Gelmez, B., & Yildiz-Pekoz, A. (2023). Lung Microbiota: Its Relationship to Respiratory System Diseases and Approaches for Lung-Targeted Probiotic Bacteria Delivery. Molecular Pharmaceutics, 20(7), 3320–3337. https://doi.org/10.1021/acs.molpharmaceut.3c00323 DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00323

Zong, R., Ruan, H., Liu, C., Fan, S., & Li, J. (2023). Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy. Pharmaceutics, 15(10), 2490. https://doi.org/10.3390/pharmaceutics15102490 DOI: https://doi.org/10.3390/pharmaceutics15102490